


IN THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (original) A composition comprising
(a) a NPY5 antagonist of formula I or II



and pharmaceutically acceptable salts and esters thereof, wherein
Ar¹ is selected from the group consisting of:

- (1) aryl, and
 - (2) heteroaryl,
- wherein the aryl and heteroaryl groups are unsubstituted or optionally substituted with a substituent selected from the group consisting of:
- (a) halogen,
 - (b) nitro,
 - (c) lower alkyl,
 - (d) halo(lower)alkyl,
 - (e) hydroxy(lower)alkyl,
 - (f) cyclo(lower)alkyl,
 - (g) lower alkenyl,
 - (h) lower alkoxy,
 - (i) halo(lower)alkoxy,
 - (j) lower alkylthio,
 - (k) carboxyl,

- (l) lower alkanoyl,
- (m) lower alkoxy carbonyl,
- (n) lower alkylene optionally substituted with oxo, and
- (o) -Q-Ar²;

Ar² is selected from the group consisting of

- (1) aryl, and
- (2) heteroaryl,

wherein aryl and heteroaryl are unsubstituted or optionally substituted with a substituent selected from the group consisting of:

- (a) halogen,
- (b) cyano,
- (c) lower alkyl,
- (d) halo(lower)alkyl,
- (e) hydroxy(lower)alkyl,
- (f) hydroxy,
- (g) lower alkoxy,
- (h) halo(lower)alkoxy,
- (i) lower alkylamino,
- (j) di-lower alkylamino,
- (k) lower alkanoyl, and
- (l) aryl;

n is 0 or 1;

Q is selected from the group consisting of a single bond or carbonyl;

T, U, V and W are each independently selected from the group consisting of

- (1) nitrogen, and
- (2) methine,

wherein the methine group is unsubstituted or optionally substituted with a substituent selected from the group consisting of

- (a) halogen,
- (b) lower alkyl,
- (c) hydroxy, and
- (d) lower alkoxy, and

wherein at least two of T, U, V, and W are methine;

X is selected from the group consisting of

- (1) nitrogen, and
- (2) methine; and

Y is selected from the group consisting of

- (1) imino, unsubstituted or optionally substituted with lower alkyl, and
- (2) oxygen; and

(b) an antiobesity agent selected from the group consisting of:

- (1) 5HT transporter inhibitor;
- (2) NE transporter inhibitor;
- (3) CB-1 antagonist/inverse agonist;
- (4) Ghrelin antagonist;
- (5) H3 antagonist/inverse agonist;
- (6) MCH1R antagonist;
- (7) MCH2R agonist/antagonist;
- (8) NPY1 antagonist;
- (9) leptin;
- (10) leptin derivatives;
- (11) opioid antagonist;
- (12) orexin antagonist;
- (13) BRS3 agonist;
- (14) CCK-A agonist;
- (15) CNTF;
- (16) CNTF derivatives;
- (17) GHS agonist;
- (18) 5HT2C agonist;
- (19) monoamine reuptake inhibitor;
- (20) UCP-1, 2, and 3 activator;
- (21) β 3 agonist;
- (22) thyroid hormone β agonist;
- (23) PDE inhibitor;
- (24) FAS inhibitor;
- (25) DGAT1 inhibitor;
- (26) DGAT2 inhibitor;
- (27) ACC2 inhibitor;
- (28) glucocorticoid antagonist;
- (29) acyl-estrogens;
- (30) lipase inhibitor;

(31) fatty acid transporter inhibitor;
(32) dicarboxylate transporter inhibitor;
(33) glucose transporter inhibitor;
(34) serotonin reuptake inhibitors;
(35) metformin; and
(36) topiramate;
and pharmaceutically acceptable salts and esters thereof.

2. (original) The composition of Claim 1 wherein the anti-obesity agent is selected from the group consisting of:


(1) acyl-estrogen;
(2) CB-1 antagonist/inverse agonist;
(3) opioid antagonist;
(4) monoamine reuptake inhibitor;
(5) lipase inhibitor;
(6) leptin;
(7) CNTF;
(8) CNTF derivatives;
(9) metformin; and
(10) topiramate;
and pharmaceutically acceptable salts and esters thereof.

3. (currently amended) The composition of Claim 2 wherein the acyl-estrogen is selected from oleoyl-estrone, the monoamine reuptake inhibitor is selected from sibutramine, the CNTF derivative is selected from axokine, the lipase inhibitor is selected from orlistat, the CB-1 antagonist/inverse agonist is selected from rimonabant, and the opioid antagonist is selected from nalmefene, and the pharmaceutically acceptable salts thereof.

4. (cancelled)
5. (cancelled)
6. (cancelled)

- 7. (cancelled)
- 8. (cancelled)
- 9. (cancelled)
- 10. (cancelled)
- 11. (cancelled)

12. (original) The composition of Claim 1 wherein the NPY5 antagonist is selected from the group consisting of a compound of formula I



and pharmaceutically acceptable salts and esters thereof, wherein Ar¹ is selected from the group consisting of:

- (1) aryl, and
- (2) heteroaryl,

wherein the aryl and heteroaryl groups are unsubstituted or optionally substituted with a substituent selected from the group consisting of:

- (a) halogen,
- (b) nitro,
- (c) lower alkyl,
- (d) halo(lower)alkyl,
- (e) hydroxy(lower)alkyl,
- (f) cyclo(lower)alkyl,
- (g) lower alkenyl,
- (h) lower alkoxy,
- (i) halo(lower)alkoxy,
- (j) lower alkylthio,

- (k) carboxyl,
- (l) lower alkanoyl,
- (m) lower alkoxy carbonyl,
- (n) lower alkylene optionally substituted with oxo, and
- (o) -Q-Ar²;

Ar² is selected from the group consisting of

- (1) aryl, and
- (2) heteroaryl,

wherein aryl and heteroaryl are unsubstituted or optionally substituted with a substituent selected from the group consisting of:

- (a) halogen,
- (b) cyano,
- (c) lower alkyl,
- (d) halo(lower)alkyl,
- (e) hydroxy(lower)alkyl,
- (f) hydroxy,
- (g) lower alkoxy,
- (h) halo(lower)alkoxy,
- (i) lower alkylamino,
- (j) di-lower alkylamino,
- (k) lower alkanoyl, and
- (l) aryl;

n is 0 or 1;

Q is selected from the group consisting of a single bond or carbonyl;

T, U, V and W are each independently selected from the group consisting of

- (1) nitrogen, and
- (2) methine,

wherein the methine group is unsubstituted or optionally substituted with a substituent selected from the group consisting of

- (a) halogen,
- (b) lower alkyl,
- (c) hydroxy, and
- (d) lower alkoxy; and

~wherein at least two of T, U, V, and W are methine;

X is selected from the group consisting of

- (1) nitrogen, and

(2) methine; and
Y is selected from the group consisting of

- (1) imino, unsubstituted or optionally substituted with lower alkyl, and
- (2) oxygen.


13. (cancelled)

14. (currently amended) The composition of Claim ~~13~~ 12 wherein the NPY5 antagonist is selected from the group consisting of

- (1) 3-oxo-N-(5-phenyl-2-pyrazinyl)-spiro[isobenzofuran-1(3H),4'-piperidine]-1'-carboxamide;
 - (2) 3-oxo-N-(7-trifluoromethylpyrido[3,2-b]pyridin-2-yl)spiro-[isobenzofuran-1(3H),4'-piperidine]-1'-carboxamide;
 - (3) N-[5-(3-fluorophenyl)-2-pyrimidinyl]-3-oxospiro-[isobenzofuran-1(3H),4'-piperidine]-1'-carboxamide;
 - (4) trans-3'-oxo-N-(5-phenyl-2-pyrimidinyl)spiro[cyclohexane-1,1'(3'H)-isobenzofuran]-4-carboxamide;
 - (5) trans-3'-oxo-N-[1-(3-quinolyl)-4-imidazolyl]spiro[cyclohexane-1,1'(3'H)-isobenzofuran]-4-carboxamide;
 - (6) trans-3-oxo-N-(5-phenyl-2-pyrazinyl)spiro[4-azaiso-benzofuran-1(3H),1'-cyclohexane]-4'-carboxamide;
 - (7) trans-N-[5-(3-fluorophenyl)-2-pyrimidinyl]-3-oxospiro[5-azaisobenzofuran-1(3H),1'-cyclohexane]-4'-carboxamide;
 - (8) trans-N-[5-(2-fluorophenyl)-2-pyrimidinyl]-3-oxospiro[5-azaisobenzofuran-1(3H),1'-cyclohexane]-4'-carboxamide;
 - (9) trans-N-[1-(3,5-difluorophenyl)-4-imidazolyl]-3-oxospiro[7-azaisobenzofuran-1(3H),1'-cyclohexane]-4'-carboxamide;
 - (10) trans-3-oxo-N-(1-phenyl-4-pyrazolyl)spiro[4-azaisobenzofuran-1(3H),1'-cyclohexane]-4'-carboxamide;
 - (11) trans-N-[1-(2-fluorophenyl)-3-pyrazolyl]-3-oxospiro[6-azaisobenzofuran-1(3H),1'-cyclohexane]-4'-carboxamide;
 - (12) trans-3-oxo-N-(1-phenyl-3-pyrazolyl)spiro[6-azaisobenzofuran-1(3H),1'-cyclohexane]-4'-carboxamide; and
 - (13) trans-3-oxo-N-(2-phenyl-1,2,3-triazol-4-yl)spiro[6-azaisobenzofuran-1(3H),1'-cyclohexane]-4'-carboxamide;
- and pharmaceutically acceptable salts and esters thereof.

15. (original) A composition comprising

(a) a NPY5 antagonist of formula I or II



and pharmaceutically acceptable salts and esters thereof, wherein Ar¹ is selected from the group consisting of:

- (1) aryl, and
- (2) heteroaryl,

wherein the aryl and heteroaryl groups are unsubstituted or optionally substituted with a substituent selected from the group consisting of:

- (a) halogen,
- (b) nitro,
- (c) lower alkyl,
- (d) halo(lower)alkyl,
- (e) hydroxy(lower)alkyl,
- (f) cyclo(lower)alkyl,
- (g) lower alkenyl,
- (h) lower alkoxy,
- (i) halo(lower)alkoxy,
- (j) lower alkylthio,
- (k) carboxyl,
- (l) lower alkanoyl,
- (m) lower alkoxy carbonyl,
- (n) lower alkylene optionally substituted with oxo, and
- (o) -Q-Ar²;

Ar² is selected from the group consisting of

- (1) aryl, and
- (2) heteroaryl,

wherein aryl and heteroaryl are unsubstituted or optionally substituted with a substituent selected from the group consisting of:

- (a) halogen,
- (b) cyano,
- (c) lower alkyl,
- (d) halo(lower)alkyl,
- (e) hydroxy(lower)alkyl,
- (f) hydroxy,
- (g) lower alkoxy,
- (h) halo(lower)alkoxy,
- (i) lower alkylamino,
- (j) di-lower alkylamino,
- (k) lower alkanoyl, and
- (l) aryl;

n is 0 or 1;

Q is selected from the group consisting of a single bond or carbonyl;

T, U, V and W are each independently selected from the group consisting of

- (1) nitrogen, and
- (2) methine,

wherein the methine group is unsubstituted or optionally substituted with a substituent selected from the group consisting of

- (a) halogen,
- (b) lower alkyl,
- (c) hydroxy, and
- (d) lower alkoxy, and

wherein at least two of T, U, V, and W are methine;

X is selected from the group consisting of

- (1) nitrogen, and
- (2) methine; and

Y is selected from the group consisting of

- (1) imino, unsubstituted or optionally substituted with lower alkyl, and
- (2) oxygen; and

(b) an anti-obesity agent selected from the group consisting of:

- (1) aminorex;

- (2) amphechloral;
- (3) amphetamine;
- (4) benzphetamine;
- (5) chlorphentermine;
- (6) clobenzorex;
- (7) cloforex;
- (8) clominorex;
- (9) clortermine;
- (10) cyclexedrine;
- (11) dexfenfluramine;
- (12) dextroamphetamine;
- (13) diethylpropion;
- (14) diphemethoxidine,
- (15) N-ethylamphetamine;
- (16) fenbutrazate;
- (17) fenfluramine;
- (18) fenisorex;
- (19) fenproporex;
- (20) fludorex;
- (21) fluminorex;
- (22) furfurylmethylamphetamine;
- (23) levamfetamine;
- (24) levophacetoperane;
- (25) mazindol;
- (26) mefenorex;
- (27) metamfepramone;
- (28) methamphetamine;
- (29) norpseudoephedrine;
- (30) pentorex;
- (31) phendimetrazine;
- (32) phenmetrazine;
- (33) phentermine;
- (34) phenylpropanolamine; and
- (35) picilorex;

and pharmaceutically acceptable salts thereof.

16. (original) A composition comprising

(a) a NPY5 antagonist selected from the group consisting of:

- (1) 3-oxo-N-(5-phenyl-2-pyrazinyl)-spiro[isobenzofuran-1(3H),4'-piperidine]-1'-carboxamide;
- (2) 3-oxo-N-(7-trifluoromethylpyrido[3,2-b]pyridin-2-yl)spiro-[isobenzofuran-1(3H),4'-piperidine]-1'-carboxamide;
- (3) N-[5-(3-fluorophenyl)-2-pyrimidinyl]-3-oxospiro-[isobenzofuran-1(3H),4'-piperidine]-1'-carboxamide;
- (4) trans-3'-oxo-N-(5-phenyl-2-pyrimidinyl)spiro[cyclohexane-1,1'(3'H)-isobenzofuran]-4-carboxamide;
- (5) trans-3'-oxo-N-[1-(3-quinolyl)-4-imidazolyl]spiro[cyclohexane-1,1'(3'H)-isobenzofuran]-4-carboxamide;
- (6) trans-3-oxo-N-(5-phenyl-2-pyrazinyl)spiro[4-azaisobenzofuran-1(3H),1'-cyclohexane]-4'-carboxamide;
- (7) trans-N-[5-(3-fluorophenyl)-2-pyrimidinyl]-3-oxospiro[5-azaisobenzofuran-1(3H),1'-cyclohexane]-4'-carboxamide;
- (8) trans-N-[5-(2-fluorophenyl)-2-pyrimidinyl]-3-oxospiro[5-azaisobenzofuran-1(3H),1'-cyclohexane]-4'-carboxamide;
- (9) trans-N-[1-(3,5-difluorophenyl)-4-imidazolyl]-3-oxospiro[7-azaisobenzofuran-1(3H),1'-cyclohexane]-4'-carboxamide;
- (10) trans-3-oxo-N-(1-phenyl-4-pyrazolyl)spiro[4-azaisobenzofuran-1(3H),1'-cyclohexane]-4'-carboxamide;
- (12) trans-N-[1-(2-fluorophenyl)-3-pyrazolyl]-3-oxospiro[6-azaisobenzofuran-1(3H),1'-cyclohexane]-4'-carboxamide;
- (13) trans-3-oxo-N-(1-phenyl-3-pyrazolyl)spiro[6-azaisobenzofuran-1(3H),1'-cyclohexane]-4'-carboxamide; and
- (14) trans-3-oxo-N-(2-phenyl-1,2,3-triazol-4-yl)spiro[6-azaisobenzofuran-1(3H),1'-cyclohexane]-4'-carboxamide;

and pharmaceutically acceptable salts and esters thereof; and

(b) a Mc4r agonist selected from the group consisting of:

- (1) 2-[2-(1-{{(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl) pyrrolidin-3-yl}carbonyl}piperidin-4-yl)-5-chloro phenyl]-N-methylcarboxamide;
- (2) 2-[2-(1-{{(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl) pyrrolidin-3-yl}carbonyl}piperidin-4-yl)-5-fluoro-phenyl]-N-methylcarboxamide;
- (3) 2-[2-(1-{{(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl) pyrrolidin-3-yl}carbonyl}piperidin-4-yl)-5-methyl-phenyl]-N-methylcarboxamide;

- (4) 2-[2-(1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl) pyrrolidin-3-yl]carbonyl}piperidin-4-yl)-phenyl]-N-methylcarboxamide;
- (5) 2-[2-(1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl) pyrrolidin-3-yl]carbonyl}piperidin-4-yl)-4-methyl-phenyl]-N-methylcarboxamide;
- (6) 2-[2-(1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl) pyrrolidin-3-yl]carbonyl}piperidin-4-yl)-4-fluoro-phenyl]-N-methylcarboxamide;
- (7) 4-[2-(2-azetidin-1-yl-1(S)-methyl-2-oxoethyl)-4-chlorophenyl]-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidin-3-yl]carbonyl}piperidine;
- (8) 4-[2-(2-azetidin-1-yl-1(R)-methyl-2-oxoethyl)-4-chlorophenyl]-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidin-3-yl]carbonyl}piperidine;
- (9) 4-[2-(2-azetidin-1-yl-1,1-dimethyl-2-oxoethyl)-4-chlorophenyl]-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidin-3-yl]carbonyl}piperidine;
- (10) 4-[2-(2-azetidin-1-yl-1-cyclopropyl-2-oxoethyl)-4-chlorophenyl]-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidin-3-yl]carbonyl}piperidine;
- (11) 4-[2-(2-azetidin-1-yl-1,1-dimethyl-2-oxoethyl)-4-fluorophenyl]-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidin-3-yl]carbonyl}piperidine;
- (12) 4-[2-(2-azetidin-1-yl-1-cyclopropyl-2-oxoethyl)-4-fluorophenyl]-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidin-3-yl]carbonyl}piperidine;
- (13) N-{(1S)-1-[2-(1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)-pyrrolidin-3-yl]carbonyl}piperidin-4-yl)-5-chlorophenyl]ethyl}acetamide;
- (14) N-{(1R)-1-[2-(1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)-pyrrolidin-3-yl]carbonyl}piperidin-4-yl)-5-chlorophenyl]ethyl}acetamide;
- (15) N-{1-[2-(1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidin-3-yl]carbonyl}piperidin-4-yl)-5-chlorophenyl]-1-methylethyl}acetamide;
- (16) N-{1-[2-(1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidin-3-yl]carbonyl}piperidin-4-yl)-5-fluorophenyl]ethyl}acetamide;
- (17) N-{1-[2-(1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidin-3-yl]carbonyl}piperidin-4-yl)-5-chlorophenyl]ethyl}cyclobutanecarboxamide;
- (18) N-{1-[2-(1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidin-3-yl]carbonyl}piperidin-4-yl)-5-chlorophenyl]ethyl}propanamide;
- (19) N-{1-[2-(1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluoro-phenyl)pyrrolidin-3-yl]carbonyl}piperidin-4-yl)-5-chlorophenyl]ethyl}-N-methylurea;
- (20) Methyl-2-[2-(1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)-pyrrolidin-3-yl]carbonyl}piperidin-4-yl)-5-chlorophenyl]-2-methylpropanoate;

- (21) N-{1-[2-(1-[(3S,4R)-1-tert-butyl-4-(2,4-difluoro-phenyl)pyrrolidin-3-yl]carbonyl}piperidin-4-yl)-5-fluorophenyl]-1-methylethyl}acetamide;
- (22) N-{1-[2-(1-[(3S,4R)-1-tert-butyl-4-(2,4-difluoro-phenyl)pyrrolidin-3-yl]carbonyl}piperidin-4-yl)-5-fluorophenyl]ethyl}-N-methylurea;
- (23) N-{1-[2-(1-[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidin-3-yl]carbonyl}piperidin-4-yl)-5-fluorophenyl]ethyl}cyclobutanecarboxamide;
- (24) N-{1-[2-(1-[(3S,4R)-1-tert-butyl-4-(2,4-difluoro-phenyl)pyrrolidin-3-yl]carbonyl}piperidin-4-yl)-5-fluorophenyl]ethyl}propanamide;
- (25) N-((1S)-1-[2-(1-[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)-pyrrolidin-3-yl]carbonyl}piperidin-4-yl)-5-fluorophenyl]ethyl}acetamide;
- (26) N-((1S)-1-[2-(1-[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)-pyrrolidin-3-yl]carbonyl}piperidin-4-yl)-5-chlorophenyl]propyl}acetamide; and
- (27) N-((1S)-1-[2-(1-[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)-pyrrolidin-3-yl]carbonyl}piperidin-4-yl)-5-chlorophenyl]ethyl}pyrimidine-5-carboxamide;
- and pharmaceutically acceptable salts thereof.

17. (original) A composition comprising

(a) a NPY5 antagonist selected from the group consisting of:

- (1) 3-oxo-N-(5-phenyl-2-pyrazinyl)-spiro[isobenzofuran-1(3H),4'-piperidine]-1'-carboxamide;
- (2) 3-oxo-N-(7-trifluoromethylpyrido[3,2-b]pyridin-2-yl)spiro-[isobenzofuran-1(3H),4'-piperidine]-1'-carboxamide;
- (3) N-[5-(3-fluorophenyl)-2-pyrimidinyl]-3-oxospiro-[isobenzofuran-1(3H),4'-piperidine]-1'-carboxamide;
- (4) trans-3'-oxo-N-(5-phenyl-2-pyrimidinyl)spiro[cyclohexane-1,1'(3'H)-isobenzofuran]-4-carboxamide;
- (5) trans-3'-oxo-N-[1-(3-quinolyl)-4-imidazolyl]spiro[cyclohexane-1,1'(3'H)-isobenzofuran]-4-carboxamide;
- (6) trans-3-oxo-N-(5-phenyl-2-pyrazinyl)spiro[4-azaiso-benzofuran-1(3H),1'-cyclohexane]-4'-carboxamide;
- (7) trans-N-[5-(3-fluorophenyl)-2-pyrimidinyl]-3-oxospiro[5-azaisobenzofuran-1(3H),1'-cyclohexane]-4'-carboxamide;
- (8) trans-N-[5-(2-fluorophenyl)-2-pyrimidinyl]-3-oxospiro[5-azaisobenzofuran-1(3H),1'-cyclohexane]-4'-carboxamide;

(9) trans-N-[1-(3,5-difluorophenyl)-4-imidazolyl]-3-oxospiro[7-azaisobenzofuran-1(3H),1'-cyclohexane]-4'-carboxamide;

(10) trans-3-oxo-N-(1-phenyl-4-pyrazolyl)spiro[4-azaisobenzofuran-1(3H),1'-cyclohexane]-4'-carboxamide;

(11) trans-N-[1-(2-fluorophenyl)-3-pyrazolyl]-3-oxospiro[6-azaisobenzofuran-1(3H),1'-cyclohexane]-4'-carboxamide;

(12) trans-3-oxo-N-(1-phenyl-3-pyrazolyl)spiro[6-azaisobenzofuran-1(3H),1'-cyclohexane]-4'-carboxamide; and

(13) trans-3-oxo-N-(2-phenyl-1,2,3-triazol-4-yl)spiro[6-azaisobenzofuran-1(3H),1'-cyclohexane]-4'-carboxamide;

and pharmaceutically acceptable salts and esters thereof; and

(b) a Mc4r agonist selected from the group consisting of:

(1) N-{(1S)-1-[2-(1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)-pyrrolidin-3-yl]carbonyl}piperidin-4-yl)-5-fluorophenyl]ethyl}acetamide,

(2) N-{(1S)-1-[2-(1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)-pyrrolidin-3-yl]carbonyl}piperidin-4-yl)-5-chlorophenyl]propyl}acetamide,

(3) N-{(1S)-1-[2-(1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)-pyrrolidin-3-yl]carbonyl}piperidin-4-yl)-5-chlorophenyl]ethyl}acetamide, ,

(4) 2-[2-(1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl) pyrrolidin-3-yl]carbonyl}piperidin-4-yl)-5-chloro phenyl]-N-methylcarboxamide,

(5) N-{(1S)-1-[2-(1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)-pyrrolidin-3-yl]carbonyl}piperidin-4-yl)-5-chlorophenyl]ethyl}pyrimidine-5-carboxamide, and

(6) 4-[2-(2-azetidin-1-yl-1(S)-methyl-2-oxoethyl)-4-chlorophenyl]-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidin-3-yl]carbonyl}piperidine,
and pharmaceutically acceptable salts thereof.

18. (original) A composition according to Claim 1 further comprising a pharmaceutically acceptable carrier.

19. (cancelled)

20. (cancelled)

21. (original) A method of preventing obesity in a subject at risk

(a) a prophylactically effective amount of a NPY5 antagonist of Formula I or II:



(1) aryl, and
(2) heteroaryl,

- (a) halogen,
- (b) nitro,
- (c) lower alkyl,
- (d) halo(lower)alkyl,
- (e) hydroxy(lower)alkyl,
- (f) cyclo(lower)alkyl,
- (g) lower alkenyl,
- (h) lower alkoxy,
- (i) halo(lower)alkoxy,
- (j) lower alkylthio,
- (k) carboxyl,
- (l) lower alkanoyl,
- (m) lower alkoxycarbonyl,
- (n) lower alkylene optionally substituted with oxo, and
- (o) -Q-Ar²;

Ar² is selected from the group consisting of

(1) aryl, and

(2) heteroaryl,

wherein aryl and heteroaryl are unsubstituted or optionally substituted with a substituent selected from the group consisting of:

(a) halogen,

(b) cyano,

(c) lower alkyl,

(d) halo(lower)alkyl,

(e) hydroxy(lower)alkyl,

(f) hydroxy,

(g) lower alkoxy,

(h) halo(lower)alkoxy,

(i) lower alkylamino,

(j) di-lower alkylamino,

(k) lower alkanoyl, and

(l) aryl;

n is 0 or 1;

Q is selected from the group consisting of a single bond or carbonyl;

T, U, V and W are each independently selected from the group consisting of

(1) nitrogen, and

(2) methine,

wherein the methine group is unsubstituted or optionally substituted with a substituent selected from the group consisting of

(a) halogen,

(b) lower alkyl,

(c) hydroxy, and

(d) lower alkoxy, and

wherein at least two of T, U, V, and W are methine;

X is selected from the group consisting of

(1) nitrogen, and

(2) methine; and

Y is selected from the group consisting of

(1) imino, unsubstituted or optionally substituted with lower alkyl, and

(2) oxygen; and


(b) a prophylactically effective amount of an anti-obesity agent selected from the group consisting of:

(1) 5HT transporter inhibitor;

- (2) NE transporter inhibitor;
- (3) CB-1 antagonist/inverse agonist;
- (4) Ghrelin antagonist;
- (5) H3 antagonist/inverse agonist;
- (6) MCH1R antagonist;
- (7) MCH2R agonist/antagonist;
- (8) NPY1 antagonist;
- (9) leptin;
- (10) leptin derivatives;
- (11) opioid antagonist;
- (12) orexin antagonist;
- (13) BRS3 agonist;
- (14) CCK-A agonist;
- (15) CNTF;
- (16) CNTF derivatives;
- (17) GHS agonist;
- (18) 5HT2C agonist;
- (19) monoamine reuptake inhibitor;
- (20) UCP-1, 2, and 3 activator;
- (21) β 3 agonist;
- (22) thyroid hormone β agonist;
- (23) PDE inhibitor;
- (24) FAS inhibitor;
- (25) DGAT1 inhibitor;
- (26) DGAT2 inhibitor;
- (27) ACC2 inhibitor;
- (28) glucocorticoid antagonist;
- (29) acyl-estrogens;
- (30) lipase inhibitor;
- (31) fatty acid transporter inhibitor;
- (32) dicarboxylate transporter inhibitor;
- (33) glucose transporter inhibitor;
- (34) serotonin reuptake inhibitors;
- (35) metformin; and

(36) topiramate;
and pharmaceutically acceptable salts and esters thereof.

22. (currently amended) A The method of treating a subject having a disorder associated with excessive food intake comprising administration of
(a) a therapeutically effective amount of a NPY5 antagonist of Formula I or II:



and pharmaceutically acceptable salts and esters thereof, wherein Ar¹ is selected from the group consisting of:

- (1) aryl, and
 - (2) heteroaryl,
- wherein the aryl and heteroaryl groups are unsubstituted or optionally substituted with a substituent selected from the group consisting of:
- (a) halogen,
 - (b) nitro,
 - (c) lower alkyl,
 - (d) halo(lower)alkyl,
 - (e) hydroxy(lower)alkyl,
 - (f) cyclo(lower)alkyl,
 - (g) lower alkenyl,
 - (h) lower alkoxy,
 - (i) halo(lower)alkoxy,
 - (j) lower alkylthio,
 - (k) carboxyl,
 - (l) lower alkanoyl,

- (m) lower alkoxy carbonyl,
- (n) lower alkylene optionally substituted with oxo, and
- (o) -Q-Ar²;

Ar² is selected from the group consisting of

- (1) aryl, and
- (2) heteroaryl,

wherein aryl and heteroaryl are unsubstituted or optionally substituted with a substituent selected from the group consisting of:

- (a) halogen,
- (b) cyano,
- (c) lower alkyl,
- (d) halo(lower)alkyl,
- (e) hydroxy(lower)alkyl,
- (f) hydroxy,
- (g) lower alkoxy,
- (h) halo(lower)alkoxy,
- (i) lower alkylamino,
- (j) di-lower alkylamino,
- (k) lower alkanoyl, and
- (l) aryl;

n is 0 or 1;

Q is selected from the group consisting of a single bond or carbonyl;

T, U, V and W are each independently selected from the group consisting of

- (1) nitrogen, and
- (2) methine,

wherein the methine group is unsubstituted or optionally substituted with a substituent selected from the group consisting of

- (a) halogen,
- (b) lower alkyl,
- (c) hydroxy, and
- (d) lower alkoxy, and

wherein at least two of T, U, V, and W are methine;

X is selected from the group consisting of

- (1) nitrogen, and
- (2) methine; and

Y is selected from the group consisting of

- (1) imino, unsubstituted or optionally substituted with lower alkyl, and
- (2) oxygen; and

(b) a therapeutically effective amount of an anti-obesity agent selected from the group consisting of:

- (1) 5HT transporter inhibitor;
- (2) NE transporter inhibitor;
- (3) CB-1 antagonist/inverse agonist;
- (4) Ghrelin antagonist;
- (5) H3 antagonist/inverse agonist;
- (6) MCH1R antagonist;
- (7) MCH2R agonist/antagonist;
- (8) NPY1 antagonist;
- (9) leptin;
- (10) leptin derivatives;
- (11) opioid antagonist;
- (12) orexin antagonist;
- (13) BRS3 agonist;
- (14) CCK-A agonist;
- (15) CNTF;
- (16) CNTF derivatives;
- (17) GHS agonist;
- (18) 5HT2C agonist;
- (19) monoamine reuptake inhibitor;
- (20) UCP-1, 2, and 3 activator;
- (21) β 3 agonist;
- (22) thyroid hormone β agonist;
- (23) PDE inhibitor;
- (24) FAS inhibitor;
- (25) DGAT1 inhibitor;
- (26) DGAT2 inhibitor;
- (27) ACC2 inhibitor;
- (28) glucocorticoid antagonist;
- (29) acyl-estrogens;
- (30) lipase inhibitor;

- (31) fatty acid transporter inhibitor;
- (32) dicarboxylate transporter inhibitor;
- (33) glucose transporter inhibitor;
- (34) serotonin reuptake inhibitors;
- (35) metformin; and
- (36) topiramate;

and pharmaceutically acceptable salts and esters thereof;
to a subject in need of such treatment.

23. (currently amended) The method according to Claim 22 wherein the disorder associated with excessive food intake is selected from obesity and an obesity-related disorder.

24. (cancelled)

25. (currently amended) The method according to Claim ~~24~~ 23 wherein the obesity-related disorder is selected from: overeating; bulimia; hypertension; diabetes, elevated plasma insulin concentrations; insulin resistance; dyslipidemia; hyperlipidemia; endometrial, breast, prostate and colon cancer; osteoarthritis; obstructive sleep apnea; cholelithiasis; gallstones; coronary heart disease; abnormal heart rhythms; heart arrhythmias; myocardial infarction; polycystic ovarian disease; craniopharyngioma; the Prader-Willi Syndrome; Frohlich's syndrome; GH-deficient subjects; normal variant short stature; Turner's syndrome; and acute lymphoblastic leukemia.

26. (original) The method according to Claim 25 wherein the obesity-related disorder is diabetes.

27. (cancelled)

28. (cancelled)

29. (cancelled)

30. (cancelled)

31. (cancelled)

32. (cancelled)

33. (cancelled)

34. (original) A method of preventing obesity in a subject at risk

for obesity comprising administration to said subject

(a) a prophylactically effective amount of a NPY5 antagonist selected from the group consisting of:

- (1) 3-oxo-N-(5-phenyl-2-pyrazinyl)-spiro[isobenzofuran-1(3H),4'-piperidine]-1'-carboxamide;
- (2) 3-oxo-N-(7-trifluoromethylpyrido[3,2-b]pyridin-2-yl)spiro-[isobenzofuran-1(3H),4'-piperidine]-1'-carboxamide;
- (3) N-[5-(3-fluorophenyl)-2-pyrimidinyl]-3-oxospiro-[isobenzofuran-1(3H),4'-piperidine]-1'-carboxamide;
- (4) trans-3'-oxo-N-(5-phenyl-2-pyrimidinyl)spiro[cyclohexane-1,1'(3'H)-isobenzofuran]-4-carboxamide;
- (5) trans-3'-oxo-N-[1-(3-quinolyl)-4-imidazolyl]spiro[cyclohexane-1,1'(3'H)-isobenzofuran]-4-carboxamide;
- (6) trans-3-oxo-N-(5-phenyl-2-pyrazinyl)spiro[4-azaiso-benzofuran-1(3H),1'-cyclohexane]-4'-carboxamide;
- (7) trans-N-[5-(3-fluorophenyl)-2-pyrimidinyl]-3-oxospiro[5-azaisobenzofuran-1(3H),1'-cyclohexane]-4'-carboxamide;
- (8) trans-N-[5-(2-fluorophenyl)-2-pyrimidinyl]-3-oxospiro[5-azaisobenzofuran-1(3H),1'-cyclohexane]-4'-carboxamide;
- (9) trans-N-[1-(3,5-difluorophenyl)-4-imidazolyl]-3-oxospiro[7-azaisobenzofuran-1(3H),1'-cyclohexane]-4'-carboxamide;
- (10) trans-3-oxo-N-(1-phenyl-4-pyrazolyl)spiro[4-azaisobenzofuran-1(3H),1'-cyclohexane]-4'-carboxamide;
- (11) trans-N-[1-(2-fluorophenyl)-3-pyrazolyl]-3-oxospiro[6-azaisobenzofuran-1(3H),1'-cyclohexane]-4'-carboxamide;
- (12) trans-3-oxo-N-(1-phenyl-3-pyrazolyl)spiro[6-azaisobenzofuran-1(3H),1'-cyclohexane]-4'-carboxamide; and
- (13) trans-3-oxo-N-(2-phenyl-1,2,3-triazol-4-yl)spiro[6-azaisobenzofuran-1(3H),1'-cyclohexane]-4'-carboxamide;

and pharmaceutically acceptable salts and esters thereof; and

(b) a prophylactically effective amount of a Mc4r agonist selected from the group consisting of:

- (1) 2-[2-(1-[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl) pyrrolidin-3-yl]carbonyl}piperidin-4-yl)-5-chloro phenyl]-N-methylcarboxamide;

- (2) 2-[2-(1-{{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidin-3-yl]carbonyl}piperidin-4-yl)-5-fluoro-phenyl]-N-methylcarboxamide;
- (3) 2-[2-(1-{{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidin-3-yl]carbonyl}piperidin-4-yl)-5-methyl-phenyl]-N-methylcarboxamide;
- (4) 2-[2-(1-{{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidin-3-yl]carbonyl}piperidin-4-yl)-phenyl]-N-methylcarboxamide;
- (5) 2-[2-(1-{{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidin-3-yl]carbonyl}piperidin-4-yl)-4-methyl-phenyl]-N-methylcarboxamide;
- (6) 2-[2-(1-{{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidin-3-yl]carbonyl}piperidin-4-yl)-4-fluoro-phenyl]-N-methylcarboxamide;
- (7) 4-[2-(2-azetidin-1-yl-1(S)-methyl-2-oxoethyl)-4-chlorophenyl]-1-{{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidin-3-yl]carbonyl}piperidine;
- (8) 4-[2-(2-azetidin-1-yl-1(R)-methyl-2-oxoethyl)-4-chlorophenyl]-1-{{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidin-3-yl]carbonyl}piperidine;
- (9) 4-[2-(2-azetidin-1-yl-1,1-dimethyl-2-oxoethyl)-4-chlorophenyl]-1-{{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidin-3-yl]carbonyl}piperidine;
- (10) 4-[2-(2-azetidin-1-yl-1-cyclopropyl-2-oxoethyl)-4-chlorophenyl]-1-{{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidin-3-yl]carbonyl}piperidine;
- (11) 4-[2-(2-azetidin-1-yl-1,1-dimethyl-2-oxoethyl)-4-fluorophenyl]-1-{{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidin-3-yl]carbonyl}piperidine;
- (12) 4-[2-(2-azetidin-1-yl-1-cyclopropyl-2-oxoethyl)-4-fluorophenyl]-1-{{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidin-3-yl]carbonyl}piperidine;
- (13) N-{{(1S)-1-[2-(1-{{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidin-3-yl]carbonyl}piperidin-4-yl)-5-chlorophenyl]ethyl}acetamide};
- (14) N-{{(1R)-1-[2-(1-{{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidin-3-yl]carbonyl}piperidin-4-yl)-5-chlorophenyl]ethyl}acetamide};
- (15) N-{{1-[2-(1-{{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidin-3-yl]carbonyl}piperidin-4-yl)-5-chlorophenyl]-1-methylethyl}acetamide};
- (16) N-{{1-[2-(1-{{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidin-3-yl]carbonyl}piperidin-4-yl)-5-fluorophenyl]ethyl}acetamide};
- (17) N-{{1-[2-(1-{{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidin-3-yl]carbonyl}piperidin-4-yl)-5-chlorophenyl]ethyl}cyclobutanecarboxamide};
- (18) N-{{1-[2-(1-{{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidin-3-yl]carbonyl}piperidin-4-yl)-5-chlorophenyl]ethyl}propanamide};

- (19) N-{1-[2-(1-{{[(3S,4R)-1-tert-butyl-4-(2,4-difluoro-phenyl)pyrrolidin-3-yl]carbonyl}piperidin-4-yl)-5-chlorophenyl]ethyl}-N-methylurea;
- (20) Methyl-2-[2-(1-{{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)-pyrrolidin-3-yl]carbonyl}piperidin-4-yl)-5-chlorophenyl]-2-methylpropanoate;
- (21) N-{1-[2-(1-{{[(3S,4R)-1-tert-butyl-4-(2,4-difluoro-phenyl)pyrrolidin-3-yl]carbonyl}piperidin-4-yl)-5-fluorophenyl]-1-methylethyl}acetamide;
- (22) N-{1-[2-(1-{{[(3S,4R)-1-tert-butyl-4-(2,4-difluoro-phenyl)pyrrolidin-3-yl]carbonyl}piperidin-4-yl)-5-fluorophenyl]ethyl}-N-methylurea;
- (23) N-{1-[2-(1-{{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidin-3-yl]carbonyl}piperidin-4-yl)-5-fluorophenyl]ethyl}cyclobutanecarboxamide;
- (24) N-{1-[2-(1-{{[(3S,4R)-1-tert-butyl-4-(2,4-difluoro-phenyl)pyrrolidin-3-yl]carbonyl}piperidin-4-yl)-5-fluorophenyl]ethyl}propanamide;
- (25) N-{{(1S)-1-[2-(1-{{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)-pyrrolidin-3-yl]carbonyl}piperidin-4-yl)-5-fluorophenyl]ethyl}acetamide;
- (26) N-{{(1S)-1-[2-(1-{{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)-pyrrolidin-3-yl]carbonyl}piperidin-4-yl)-5-chlorophenyl]propyl}acetamide; and
- (27) N-{{(1S)-1-[2-(1-{{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)-pyrrolidin-3-yl]carbonyl}piperidin-4-yl)-5-chlorophenyl]ethyl}pyrimidine-5-carboxamide;
and pharmaceutically acceptable salts thereof.

35. (currently amended) A The method of treating a subject having a disorder associated with excessive food intake comprising administration of
(a) a therapeutically effective amount of a NPY5 antagonist selected from the group consisting of:

- (1) 3-oxo-N-(5-phenyl-2-pyrazinyl)-spiro[isobenzofuran-1(3H),4'-piperidine]-1'-carboxamide;
- (2) 3-oxo-N-(7-trifluoromethylpyrido[3,2-b]pyridin-2-yl)spiro-[isobenzofuran-1(3H),4'-piperidine]-1'-carboxamide;
- (3) N-[5-(3-fluorophenyl)-2-pyrimidinyl]-3-oxospiro-[isobenzofuran-1(3H),4'-piperidine]-1'-carboxamide;
- (4) trans-3'-oxo-N-(5-phenyl-2-pyrimidinyl)spiro[cyclohexane-1,1'(3'H)-isobenzofuran]-4-carboxamide;
- (5) trans-3'-oxo-N-[1-(3-quinolyl)-4-imidazolyl]spiro[cyclohexane-1,1'(3'H)-isobenzofuran]-4-carboxamide;

- (6) trans-3-oxo-N-(5-phenyl-2-pyrazinyl)spiro[4-azaiso-benzofuran-1(3H),1'-cyclohexane]-4'-carboxamide;
- (7) trans-N-[5-(3-fluorophenyl)-2-pyrimidinyl]-3-oxospiro[5-azaisobenzofuran-1(3H),1'-cyclohexane]-4'-carboxamide;
- (8) trans-N-[5-(2-fluorophenyl)-2-pyrimidinyl]-3-oxospiro[5-azaisobenzofuran-1(3H),1'-cyclohexane]-4'-carboxamide;
- (9) trans-N-[1-(3,5-difluorophenyl)-4-imidazolyl]-3-oxospiro[7-azaisobenzofuran-1(3H),1'-cyclohexane]-4'-carboxamide;
- (10) trans-3-oxo-N-(1-phenyl-4-pyrazolyl)spiro[4-azaisobenzofuran-1(3H),1'-cyclohexane]-4'-carboxamide;
- (11) trans-N-[1-(2-fluorophenyl)-3-pyrazolyl]-3-oxospiro[6-azaisobenzofuran-1(3H),1'-cyclohexane]-4'-carboxamide;
- (12) trans-3-oxo-N-(1-phenyl-3-pyrazolyl)spiro[6-azaisobenzofuran-1(3H),1'-cyclohexane]-4'-carboxamide; and
- (13) trans-3-oxo-N-(2-phenyl-1,2,3-triazol-4-yl)spiro[6-azaisobenzofuran-1(3H),1'-cyclohexane]-4'-carboxamide;

and pharmaceutically acceptable salts and esters thereof; and

(b) a therapeutically effective amount of a Mc4r agonist selected from the group consisting of:

- (1) 2-[2-(1-{{(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl) pyrrolidin-3-yl}carbonyl}piperidin-4-yl)-5-chloro phenyl]-N-methylcarboxamide;
- (2) 2-[2-(1-{{(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl) pyrrolidin-3-yl}carbonyl}piperidin-4-yl)-5-fluoro-phenyl]-N-methylcarboxamide;
- (3) 2-[2-(1-{{(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl) pyrrolidin-3-yl}carbonyl}piperidin-4-yl)-5-methyl-phenyl]-N-methylcarboxamide;
- (4) 2-[2-(1-{{(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl) pyrrolidin-3-yl}carbonyl}piperidin-4-yl)-phenyl]-N-methylcarboxamide;
- (5) 2-[2-(1-{{(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl) pyrrolidin-3-yl}carbonyl}piperidin-4-yl)-4-methyl-phenyl]-N-methylcarboxamide;
- (6) 2-[2-(1-{{(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl) pyrrolidin-3-yl}carbonyl}piperidin-4-yl)-4-fluoro-phenyl]-N-methylcarboxamide;
- (7) 4-[2-(2-azetidin-1-yl-1(S)-methyl-2-oxoethyl)-4-chlorophenyl]-1-{{(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidin-3-yl}carbonyl}piperidine;

- (8) 4-[2-(2-azetidin-1-yl-1(R)-methyl-2-oxoethyl)-4-chlorophenyl]-1-{{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidin-3-yl]carbonyl}piperidine;
- (9) 4-[2-(2-azetidin-1-yl-1,1-dimethyl-2-oxoethyl)-4-chlorophenyl]-1-{{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidin-3-yl]carbonyl}piperidine;
- (10) 4-[2-(2-azetidin-1-yl-1-cyclopropyl-2-oxoethyl)-4-chlorophenyl]-1-{{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidin-3-yl]carbonyl}piperidine;
- (11) 4-[2-(2-azetidin-1-yl-1,1-dimethyl-2-oxoethyl)-4-fluorophenyl]-1-{{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidin-3-yl]carbonyl}piperidine;
- (12) 4-[2-(2-azetidin-1-yl-1-cyclopropyl-2-oxoethyl)-4-fluorophenyl]-1-{{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidin-3-yl]carbonyl}piperidine;
- (13) N-{{[(1S)-1-[2-(1-{{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)-pyrrolidin-3-yl]carbonyl}piperidin-4-yl]-5-chlorophenyl]ethyl}acetamide;
- (14) N-{{[(1R)-1-[2-(1-{{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)-pyrrolidin-3-yl]carbonyl}piperidin-4-yl]-5-chlorophenyl]ethyl}acetamide;
- (15) N-{{1-[2-(1-{{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidin-3-yl]carbonyl}piperidin-4-yl]-5-chlorophenyl]-1-methylethyl}acetamide;
- (16) N-{{1-[2-(1-{{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidin-3-yl]carbonyl}piperidin-4-yl]-5-fluorophenyl]ethyl}acetamide;
- (17) N-{{1-[2-(1-{{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidin-3-yl]carbonyl}piperidin-4-yl]-5-chlorophenyl]ethyl}cyclobutanecarboxamide;
- (18) N-{{1-[2-(1-{{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidin-3-yl]carbonyl}piperidin-4-yl]-5-chlorophenyl]ethyl}propanamide;
- (19) N-{{1-[2-(1-{{[(3S,4R)-1-tert-butyl-4-(2,4-difluoro-phenyl)pyrrolidin-3-yl]carbonyl}piperidin-4-yl]-5-chlorophenyl]ethyl}-N-methylurea;
- (20) Methyl-2-[2-(1-{{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)-pyrrolidin-3-yl]carbonyl}piperidin-4-yl]-5-chlorophenyl]-2-methylpropanoate;
- (21) N-{{1-[2-(1-{{[(3S,4R)-1-tert-butyl-4-(2,4-difluoro-phenyl)pyrrolidin-3-yl]carbonyl}piperidin-4-yl]-5-fluorophenyl]-1-methylethyl}acetamide;
- (22) N-{{1-[2-(1-{{[(3S,4R)-1-tert-butyl-4-(2,4-difluoro-phenyl)pyrrolidin-3-yl]carbonyl}piperidin-4-yl]-5-fluorophenyl]ethyl}-N-methylurea;
- (23) N-{{1-[2-(1-{{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidin-3-yl]carbonyl}piperidin-4-yl]-5-fluorophenyl]ethyl}cyclobutanecarboxamide;
- (24) N-{{1-[2-(1-{{[(3S,4R)-1-tert-butyl-4-(2,4-difluoro-phenyl)pyrrolidin-3-yl]carbonyl}piperidin-4-yl]-5-fluorophenyl]ethyl}propanamide;

(25) N-{(1S)-1-[2-(1-{{(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)-pyrrolidin-3-yl}carbonyl}piperidin-4-yl)-5-fluorophenyl]ethyl}acetamide;

(26) N-{(1S)-1-[2-(1-{{(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)-pyrrolidin-3-yl}carbonyl}piperidin-4-yl)-5-chlorophenyl]propyl}acetamide; and

(27) N-{(1S)-1-[2-(1-{{(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)-pyrrolidin-3-yl}carbonyl}piperidin-4-yl)-5-chlorophenyl]ethyl}pyrimidine-5-carboxamide;
and pharmaceutically acceptable salts thereof;
to a subject in need of such treatment.

36. (currently amended) The method according to Claim 35 wherein the disorder associated with excessive food intake is selected from obesity and an obesity-related disorder.

37. (cancelled)

38. (currently amended) The method according to Claim ~~37~~ 36 wherein the obesity-related disorder is selected from: overeating; bulimia; hypertension; diabetes, elevated plasma insulin concentrations; insulin resistance; dyslipidemia; hyperlipidemia; endometrial, breast, prostate and colon cancer; osteoarthritis; obstructive sleep apnea; cholelithiasis; gallstones; coronary heart disease; abnormal heart rhythms; heart arrhythmias; myocardial infarction; polycystic ovarian disease; craniopharyngioma; the Prader-Willi Syndrome; Frohlich's syndrome; GH-deficient subjects; normal variant short stature; Turner's syndrome; and acute lymphoblastic leukemia.

39. (original) The method according to Claim 38 wherein the obesity-related disorder is diabetes.

40. (cancelled)

41. (cancelled)

42. (cancelled)


43. (cancelled)

44. (cancelled)

45. (cancelled)

46. (cancelled)


47. (currently amended) A kit comprising at least one unit dosage of a prophylactically or therapeutically effective amount of a NPY5 antagonist of Formula I or II;



and pharmaceutically acceptable salts and esters thereof, and at least one unit dosage of a prophylactically or therapeutically effective amount of an anti-obesity agent, and pharmaceutically acceptable salts and esters thereof.

48. (original) A method of maintaining weight loss in a subject comprising administration of

(a) a therapeutically effective amount of a NPY5 antagonist of Formula I or II:



and pharmaceutically acceptable salts and esters thereof, wherein Ar¹ is selected from the group consisting of:

- (1) aryl, and
- (2) heteroaryl,

wherein the aryl and heteroaryl groups are unsubstituted or optionally substituted with a substituent selected from the group consisting of:

- (a) halogen,
- (b) nitro,
- (c) lower alkyl,
- (d) halo(lower)alkyl,
- (e) hydroxy(lower)alkyl,
- (f) cyclo(lower)alkyl,
- (g) lower alkenyl,
- (h) lower alkoxy,
- (i) halo(lower)alkoxy,
- (j) lower alkylthio,
- (k) carboxyl,
- (l) lower alkanoyl,
- (m) lower alkoxycarbonyl,
- (n) lower alkylene optionally substituted with oxo, and
- (o) -Q-Ar²;

Ar² is selected from the group consisting of

- (1) aryl, and
- (2) heteroaryl,

wherein aryl and heteroaryl are unsubstituted or optionally substituted with a substituent selected from the group consisting of:

- (a) halogen,
- (b) cyano,
- (c) lower alkyl,
- (d) halo(lower)alkyl,
- (e) hydroxy(lower)alkyl,
- (f) hydroxy,
- (g) lower alkoxy,
- (h) halo(lower)alkoxy,
- (i) lower alkylamino,
- (j) di-lower alkylamino,
- (k) lower alkanoyl, and
- (l) aryl;

n is 0 or 1;

Q is selected from the group consisting of a single bond or carbonyl;

T, U, V and W are each independently selected from the group consisting of

(1) nitrogen, and

(2) methine,

wherein the methine group is unsubstituted or optionally substituted with a substituent selected from the group consisting of

(a) halogen,

(b) lower alkyl,

(c) hydroxy, and

(d) lower alkoxy, and

wherein at least two of T, U, V, and W are methine;

X is selected from the group consisting of

(1) nitrogen, and

(2) methine; and

Y is selected from the group consisting of

(1) imino, unsubstituted or optionally substituted with lower alkyl, and

(2) oxygen; and

(b) a therapeutically effective amount of an anti-obesity agent selected from the group consisting of:

(1) 5HT transporter inhibitor;

(2) NE transporter inhibitor;

(3) CB-1 antagonist/inverse agonist;

(4) Ghrelin antagonist;

(5) H3 antagonist/inverse agonist;

(6) MCH1R antagonist;

(7) MCH2R agonist/antagonist;

(8) NPY1 antagonist;

(9) leptin;

(10) leptin derivatives;

(11) opioid antagonist;

(12) orexin antagonist;

(13) BRS3 agonist;

(14) CCK-A agonist;

(15) CNTF;

(16) CNTF derivatives;


(17) GHS agonist;

(18) 5HT2C agonist;

- (19) monoamine reuptake inhibitor;
- (20) UCP-1, 2, and 3 activator;
- (21) β 3 agonist;
- (22) thyroid hormone β agonist;
- (23) PDE inhibitor;
- (24) FAS inhibitor;
- (25) DGAT1 inhibitor;
- (26) DGAT2 inhibitor;
- (27) ACC2 inhibitor;
- (28) glucocorticoid antagonist;
- (29) acyl-estrogens;
- (30) lipase inhibitor;
- (31) fatty acid transporter inhibitor;
- (32) dicarboxylate transporter inhibitor;
- (33) glucose transporter inhibitor;
- (34) serotonin reuptake inhibitors;
- (35) metformin;
- (36) topiramate;
- (37) zonisamide;
- (38) aminorex;
- (39) ampechloral;
- (40) amphetamine;
- (41) benzphetamine;
- (42) chlorphentermine;
- (43) clobenzorex;
- (44) cloforex;
- (45) clominorex;
- (46) clortermine;
- (47) cyclexedrine;
- (48) dexfenfluramine;
- (49) dextroamphetamine;
- (50) diethylpropion;
- (51) diphemethoxidine,
- (52) N-ethylamphetamine;
- (53) fenbutrazate;

- and pharmaceutically acceptable salts and esters thereof;
to a subject in need of such treatment.

(a) a NPY5 antagonist of formula I or II



and pharmaceutically acceptable salts and esters thereof, wherein

Ar¹ is selected from the group consisting of:

(1) aryl, and

(2) heteroaryl,

wherein the aryl and heteroaryl groups are unsubstituted or optionally substituted with a substituent selected from the group consisting of:

(a) halogen,

(b) nitro,

(c) lower alkyl,

(d) halo(lower)alkyl,

(e) hydroxy(lower)alkyl,

(f) cyclo(lower)alkyl,

(g) lower alkenyl,

(h) lower alkoxy,

(i) halo(lower)alkoxy,

(j) lower alkylthio,

(k) carboxyl,

(l) lower alkanoyl,

(m) lower alkoxycarbonyl,

(n) lower alkylene optionally substituted with oxo, and

(o) -Q-Ar²;

Ar² is selected from the group consisting of

(1) aryl, and

(2) heteroaryl,

wherein aryl and heteroaryl are unsubstituted or optionally substituted with a substituent selected from the group consisting of:

(a) halogen,

(b) cyano,

(c) lower alkyl,

(d) halo(lower)alkyl,

(e) hydroxy(lower)alkyl,

(f) hydroxy,

(g) lower alkoxy,

(h) halo(lower)alkoxy,

(i) lower alkylamino,

(j) di-lower alkylamino,

(k) lower alkanoyl, and

(l) aryl;

n is 0 or 1;

Q is selected from the group consisting of a single bond or carbonyl;

T, U, V and W are each independently selected from the group consisting of

(1) nitrogen, and

(2) methine,

wherein the methine group is unsubstituted or optionally substituted with a substituent selected from the group consisting of

(a) halogen,

(b) lower alkyl,

(c) hydroxy, and

(d) lower alkoxy, and

wherein at least two of T, U, V, and W are methine;

X is selected from the group consisting of

(1) nitrogen, and

(2) methine; and

Y is selected from the group consisting of

(1) imino, unsubstituted or optionally substituted with lower alkyl, and

(2) oxygen; and

(b) an anti-obesity agent selected from the group consisting of: zonisamide, and pharmaceutically acceptable salts and esters thereof.

50. (original) A method of treating a subject having a disorder associated with excessive food intake comprising administration of the composition of Claim 49 to a subject in need thereof.

51. (currently amended) The method according to Claim 50 wherein the disorder associated with excessive food intake is selected from obesity and an obesity-related disorder selected from: overeating; bulimia; hypertension; diabetes, elevated plasma insulin concentrations; insulin resistance; dyslipidemia; hyperlipidemia; endometrial, breast, prostate and colon cancer; osteoarthritis; obstructive sleep apnea; cholelithiasis; gallstones; coronary heart disease; abnormal heart rhythms; heart arrhythmias; myocardial infarction; polycystic ovarian disease; craniopharyngioma; the Prader-Willi Syndrome; Frohlich's syndrome; GH-deficient subjects; normal variant short stature; Turner's syndrome; and acute lymphoblastic leukemia.

52. (cancelled)

Serial No.: To be Assigned
Case No.: 21141YP
Page No.: 37

53. (cancelled)

54. (cancelled)

55. (original) A method of preventing obesity in a subject at risk
for obesity comprising administration of the composition of claim 49 to said subject.